Inovio Pharmaceuticals (NASDAQ: INO) — Company Overview, News & Financial Data
Inovio Pharmaceuticals develops DNA-based immunotherapies and vaccines for cancer and infectious diseases, aiming for global health impact.
Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology firm focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines for infectious diseases and cancer. The company leverages its proprietary plasmid DNA technology to stimulate robust and specific immune responses. Inovio's pipeline includes candidates for HPV-associated diseases, cancer, and infectious diseases such as COVID-19. With a commitment to global health, Inovio aims to innovate and make accessible new vaccines and therapies that can change the course of human diseases. Additionally, the company collaborates with industry leaders and organizations worldwide to advance and expand its reach in public health.
Snapshot
Operations
Products and/or services of Inovio Pharmaceuticals
- INO-4800, a DNA vaccine candidate for COVID-19, designed to precisely target the SARS-CoV-2 virus.
- VGX-3100, a DNA-based immunotherapy for the treatment of HPV-related precancers.
- Cellectra, a proprietary smart device for delivering DNA vaccines and therapeutics directly into the skin.
- INO-5401, a combination therapy targeting glioblastoma, a lethal brain cancer, using multiple immunotherapeutic agents.
- INO-5151, a DNA-based therapy aimed at treating prostate cancer by targeting specific cancer antigens.
- DNA medicines platform, providing rapid development of vaccines and therapies for infectious diseases and cancer.
Inovio Pharmaceuticals executive team
- Jacqueline E. SheaCEO, President & Director
- Peter D. KiesChief Financial Officer
- Michael SumnerChief Medical Officer & Head of Development
- Laurent M. HumeauChief Scientific Officer & Chairman of the Scientific Advisory Board
- Robert L. CrottyGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- Jennie WillsonDirector of Communications
- E. J. BrandrethSenior Vice President of Quality Assurance
- Jeffrey SkolnikSenior Vice President of Clinical Development
- Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
- Shawn D. BridySenior Vice President of Business Development
Latest news about Inovio Pharmaceuticals
Dividend history
Dividends per share paid by Inovio Pharmaceuticals, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2017 | — | — | — | $0.2760 |
Key financials
Reported results for Inovio Pharmaceuticals, in USD.
- Market cap
- 171.6M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 65.3K | -86.8M | -84.9M | |
| 217.8K | -112.4M | -107.3M | |
| 832K | -143.9M | -135.1M | |
| 10.3M | -267.6M | -279.8M |